U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Information for Lantus (insulin glargine)
  1. Postmarket Drug Safety Information for Patients and Providers

Information for Lantus (insulin glargine)

Lantus is a long-acting modified version of human insulin (insulin analog) used to control blood sugar in patients with Type 1 and Type 2 diabetes.


To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.

Related Information

Regulatory History and Labeling from Drugs@FDA

Back to Top